New schizophrenia therapy study findings have been reported from Harvard University
2007 NOV 19 -- Fresh data on schizophrenia are presented in the report 'An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.' In this recent study, researchers in the United States conducted a study "To determine the effect of intramuscular (IM) olanzapine in severely agitated patients This was an open-label multicenter 1-week observational study of IM olanzapine treatment in severely agitated inpatients and psychiatric emergency services with bipolar mania (n=22) or schizophrenia (n=52)." "Mean change from baseline to 2 h post-first injection (LOCF) in agitation was assessed by PANSS-Excited Component (PANSS-EC) (score range: 5-35 points) mean change from baseline to 15, 30, 45, 60, 90, and 120 min post-first injection, and visit-wise mean changes from mixed-model repeated measures analysis of variance. Kaplan-Meier survival curve analyses estimated time to categorical response (rating of <or=3 points each PANSS-EC item) Two hours post-injection of olanzapine (mean dose=9.9 mg), patients exhibited mild calmness and agitation was significantly reduced by 19.2 ±1.0 points (p <0.001) (mean baseline=29.0)," wrote F. Centorrino and colleagues, Harvard University. The researchers concluded: "Over 90% of the patients received only one injection in the first 24 h and 50% had a categorical response within 30 min Severely agitated patients responded rapidly after a single injection of olanzapine with mild levels of sedation and without serious treatment-emergent adverse events." Centorrino and colleagues published their study in Human Psychopharmacology (An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Human Psychopharmacology, 2007;22(7):455-62). For additional information, contact F. Centorrino, McLean Hospital, Harvard Medical School, Boston, MA USA.. Publisher contact information for the journal Human Psychopharmacology is: John Wiley & Sons Ltd., the Atrium, Southern Gate, Chichester PO19 8SQ, W Sussex, England. Keywords: United States, Boston, Schizophrenia Therapy, Bipolar Disorder, Clinical Trial Research, Drugs, Manic-Depressive Illness, Mental Health, Olanzapine, Pharmaceuticals, Psychiatric, Psychiatry, Psychopharmacology, Schizophrenia, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
